Needham Maintains Buy on Vaxcyte, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has maintained a Buy rating on Vaxcyte (NASDAQ:PCVX) and increased the price target from $73 to $95.
February 28, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reaffirmed a Buy rating on Vaxcyte and raised the price target from $73 to $95.
The increase in price target by a reputable analyst like Joseph Stringer suggests a strong confidence in Vaxcyte's future performance. This kind of positive analyst coverage typically leads to increased investor interest and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100